All In Biotech

Drug Trial Radar · NCT03567889

Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients

An Open-Label, Randomized, Controlled Multi-Center Study of The Efficacy of Daromun (L19IL2 + L19TNF) Neoadjuvant Intratumoral Treatment Followed by Surgery and Adjuvant Therapy Versus Surgery and Adjuvant Therapy in Clinical Stage IIIB/C/D Melanoma Patients

Last checked: Nov 19, 2026Latest source record: Dec 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 186 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

186

Planned (sponsor's estimate)

Start

Sep 20, 2018

Primary completion

Dec 2027

Study completion Dec 2031

Sponsor

Lead sponsor
Philogen S.p.A.Industry
Sponsor type
Industry
First posted
Jun 26, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The trial aims to evaluate the efficacy of Daromun neoadjuvant treatment followed by surgery and adjuvant therapy to improve in a statistically significant manner the recurrence-free survival (RFS) of Stage IIIB/C/D melanoma patients with respect to the standard of care (surgery and adjuvant therapy).

Conditions

  • Melanoma Stage IIIB
  • Melanoma Stage IIIC
  • Melanoma Stage IIID

Interventions

  • DaromunDrug

    Patients will receive intratumoral administrations into injectable cutaneous, subcutaneous, and nodal tumors of Daromun once weekly for up to 4 weeks.

  • SurgeryProcedure

    Patients will receive surgery.

  • Adjuvant therapyDrug

    Patients will receive adjuvant therapy at the investigator's discretion following the surgery.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recurrence Free Survival (RFS)Time frame: From date of randomization until the date of the first recurrence or date of death from any cause, whichever occurs first assessed up to 60 months.

Locations

37 sites in 3 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Hospital

    Phoenix, Arizona · Recruiting

  • UC San Diego Moores Cancer Center

    La Jolla, California · Active not recruiting

  • UC Irvine Health-Chao Family Comprehensive Cancer Center

    Orange, California · Active not recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Winship Cancer Institute, Emory university

    Atlanta, Georgia · Recruiting

  • Rush University Medical Center

    Chicago, Illinois · Active not recruiting

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa · Active not recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • Rutgers Cancer Institute, 195 Little Albany Street

    New Brunswick, New Jersey · Recruiting

  • Ambulatory Care Center at NYC Langarone Health

    New York, New York · Active not recruiting

  • Memorial Sloan Kettering Cancer Center - Main Campus

    Ney York, New York · Recruiting

  • Duke University Medical Center - Duke Cancer Center

    Durham, North Carolina · Recruiting

  • Ohio State University Wexner Medical Center

    Columbus, Ohio · Recruiting

  • St. Luke's Cancer Center, Clinical Trial, 3rd floor, 1600 St. Luke's Blvd.

    Easton, Pennsylvania · Active not recruiting

  • Penn State Cancer Institute

    Hershey, Pennsylvania · Recruiting

  • Fox Chase Cancer Center 333 Cottman Avenue

    Philadelphia, Pennsylvania · Recruiting

  • The University of Texas M.D. Anderson Cancer Center

    Houston, Texas · Recruiting

  • Huntsman Cancer Institute, University of Utah 2000 Circle of Hope

    Salt Lake City, UT, Utah · Recruiting

  • VCU - McGlothlin Medical Education Center

    Richmond, Virginia · Recruiting

  • Hospital General Universitario de Valencia

    Valencia, Spain · Recruiting

  • Hospital Universitari Germans Trias i Pujol

    Badalona, Barcelona, Spain · Recruiting

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, Barcelona, Spain · Recruiting

  • Fir Huvh Fundacio Institut De Recerca Hospital Universitari Vall De Hebron

    Barcelona, Barcelona, Spain · Recruiting

  • Hospital Clinic Barcelona

    Barcelona, Barcelona, Spain · Recruiting

  • El Hospital Universitario De Gran Canaria Dr. Negrin

    Las Palmas de Gran Canaria, Canarie, Spain · Recruiting

  • Fundacion Onkologikoa Fundazioa

    Donostia / San Sebastian, Gipuzkoa, Spain · Recruiting

  • MD Anderson Cancer Center

    Madrid, Madrid, Spain · Active not recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, Madrid, Spain · Recruiting

  • Hospital Universitario Regional de Málaga

    Málaga, Malaga, Spain · Recruiting

  • Hospital Clínico Universitario Virgen de la Arrixaca

    Murcia, Murcia, Spain · Recruiting

  • Hospital Universitario Virgen De La Macarena

    Seville, Sevilla, Spain · Active not recruiting

  • Universitätsspital Basel

    Basel, Basel, Switzerland · Active not recruiting

  • Istituto Oncologico della Svizzera Italiana

    Bellinzona, Bellinzona, Switzerland · Recruiting

  • Insel Gruppe AG

    Bern, Canton of Bern, Switzerland · Active not recruiting

  • Hôpitaux Universitaires de Genève

    Geneva, Canton of Geneva, Switzerland · Active not recruiting

  • Kantonsspital St.Gallen

    Sankt Gallen, Canton of St. Gallen, Switzerland · Recruiting

  • Universitätsspital Zürich (USZ)

    Zurich, Canton of Zurich, Switzerland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.